Cargando…

Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells

Multidrug resistance (MDR) is one of the leading causes of treatment failure in cancer chemotherapy. One major mechanism of MDR is the overexpressing of ABC transporters, whose inhibitors hold promising potential in antagonizing MDR. Glesatinib is a dual inhibitor of c-Met and SMO that is under phas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Qingbin, Cai, Chao-Yun, Gao, Hai-Ling, Ren, Liang, Ji, Ning, Gupta, Pranav, Yang, Yuqi, Shukla, Suneet, Ambudkar, Suresh V., Yang, Dong-Hua, Chen, Zhe-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494935/ https://www.ncbi.nlm.nih.gov/pubmed/31106148 http://dx.doi.org/10.3389/fonc.2019.00313

Ejemplares similares

Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1
por: Wang, Yi-Jun, et al.
Publicado: (2017)

Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2
por: Wang, De-Shen, et al.
Publicado: (2014)

MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study
por: Wu, Zhuo-Xun, et al.
Publicado: (2022)

Screening Compounds with a Novel High-Throughput ABCB1-Mediated Efflux Assay Identifies Drugs with Known Therapeutic Targets at Risk for Multidrug Resistance Interference
por: Ansbro, Megan R., et al.
Publicado: (2013)

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Feng, Weiguo, et al.
Publicado: (2020)

VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters
por: Ji, Ning, et al.
Publicado: (2018)

Dual TTK/CLK2 inhibitor, CC‐671, selectively antagonizes ABCG2‐mediated multidrug resistance in lung cancer cells
por: Wu, Zhuo‐Xun, et al.
Publicado: (2020)

Imperatorin Restores Chemosensitivity of Multidrug-Resistant Cancer Cells by Antagonizing ABCG2-Mediated Drug Transport
por: Wu, Chung-Pu, et al.
Publicado: (2023)

Dual SMO/BRAF Inhibition by Flavonolignans from Silybum marianum †
por: Diukendjieva, Antonia, et al.
Publicado: (2020)

Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein
por: Sajid, Andaleeb, et al.
Publicado: (2020)

Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells
por: Cui, Qingbin, et al.
Publicado: (2019)

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
por: Wu, Zhuo-Xun, et al.
Publicado: (2020)

BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance
por: Ashar, Yunali V., et al.
Publicado: (2020)

The multidrug resistance transporter P-glycoprotein confers resistance to ferroptosis inducers
por: Frye, William J. E., et al.
Publicado: (2023)

Pharmacophore Modeling of Nilotinib as an Inhibitor of ATP-Binding Cassette Drug Transporters and BCR-ABL Kinase Using a Three-Dimensional Quantitative Structure–Activity Relationship Approach
por: Shukla, Suneet, et al.
Publicado: (2014)

Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna(®)) with the human ABC drug transporter P-glycoprotein
por: Shukla, Suneet, et al.
Publicado: (2014)

STAT3 is required for Smo‐dependent signaling and mediates Smo‐targeted treatment resistance and tumorigenesis in Shh medulloblastoma
por: Yuan, Liangping, et al.
Publicado: (2021)

Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents
por: Wu, Chung-Pu, et al.
Publicado: (2021)

Cryo-EM Analysis of the Conformational Landscape of Human P-glycoprotein (ABCB1) During its Catalytic Cycle
por: Frank, Gabriel A., et al.
Publicado: (2016)

Circular RNA SMO sponges miR-338-3p to promote the growth of glioma by enhancing the expression of SMO
por: Xiong, Zhiyong, et al.
Publicado: (2019)

Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
por: Ji, Ning, et al.
Publicado: (2019)

Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer
por: Yadav, Priya, et al.
Publicado: (2022)

Expression of Smo in pancreatic cancer CD44(+)CD24(+)cells and construction of a lentiviral expression vector to silence Smo
por: Cong, Peng, et al.
Publicado: (2018)

Anlotinib suppresses metastasis and multidrug resistance via dual blockade of MET/ABCB1 in colorectal carcinoma cells
por: Yan, Lin-Hai, et al.
Publicado: (2021)

A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo
por: Anreddy, Nagaraju, et al.
Publicado: (2015)

CoSMoS: Conserved Sequence Motif Search in the proteome
por: Liu, Xiao I, et al.
Publicado: (2006)

Synthesis and Smo Activity of Some Novel Benzamide Derivatives
por: Ding, Huaiwei, et al.
Publicado: (2017)

Recognizing ion ligand binding sites by SMO algorithm
por: Wang, Shan, et al.
Publicado: (2019)

Identification of a Cryptic Bacterial Promoter in Mouse (mdr1a) P-Glycoprotein cDNA
por: Pluchino, Kristen M., et al.
Publicado: (2015)

New mechanisms of multidrug resistance: an introduction to the Cancer Drug Resistance special collection
por: Gottesman, Michael M., et al.
Publicado: (2023)

The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions
por: Bhullar, Jasjeet, et al.
Publicado: (2013)

Analysis of Determinants in Filovirus Glycoproteins Required for Tetherin Antagonism
por: Gnirß, Kerstin, et al.
Publicado: (2014)

Requirements within the Ebola Viral Glycoprotein for Tetherin Antagonism
por: Vande Burgt, Nathan H., et al.
Publicado: (2015)

SMO Inhibition Modulates Cellular Plasticity and Invasiveness in Colorectal Cancer
por: Magistri, Paolo, et al.
Publicado: (2018)

PreSMo Target-Binding Signatures in Intrinsically Disordered Proteins
por: Kim, Do-Hyoung, et al.
Publicado: (2018)

SMO mutations confer poor prognosis in malignant pleural mesothelioma
por: Signorelli, Diego, et al.
Publicado: (2020)

Genetic and Epigenetic Regulation of the Smoothened Gene (SMO) in Cancer Cells
por: Lou, Hong, et al.
Publicado: (2020)

TMED2 binding restricts SMO to the ER and Golgi compartments
por: Di Minin, Giulio, et al.
Publicado: (2022)

ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel
por: Kathawala, Rishil J, et al.
Publicado: (2015)

Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire
por: Camela, Elisa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0nkrer7mas27oeqbn21e7ddjph